Subscribe
Logo smallSearch
banner

A lentiviral vector manufacturing facility opened at the Świętokrzyskie Oncology Center. This is the first step for Poland's CAR-T cell therapy

MedExpress Team

Medexpress

Published Oct. 13, 2023 14:10

A lentiviral vector manufacturing facility opened at the Świętokrzyskie Oncology Center. This is the first step for Poland's CAR-T cell therapy - Header image
fot. ŚCO
The lentiviral vector manufacturing facility was opened on Thursday (12.10.) within the structures of the Genetic Engineering Department of the Świętokrzyskie Oncology Center. It was established thanks to funding from the CAR-Net (Polish Chimeric Antigen T-cell Network) project. The goal of the CAR-NET project is to develop Polish CAR-T cell therapy, i.e. human T-cells modified by genetic engineering methods.

The Świętokrzyskie Oncology Center is responsible in the CAR-NET project for preparing a lentiviral vector that will carry genetic information inside the patient's T lymphocytes. Based on this information, the lymphocytes will build a receptor on their surface so that they can recognize and destroy cancer cells.

Biotechnologists have harnessed the natural potential of lentiviruses (in this case HIV) to infect lymphocytes. The method is safe for the patient, because for the preparation of the lentiviral vector the active virus will not be used, but only its envelope (it is produced at the Plant in an incubator in the vector production stage), in which information in the form of DNA will be placed. The task of the vector is only to transfer the information inside the T lymphocytes, it is not capable of living and multiplying on its own in the patient's body. It is such a 'molecular porter'

Download this article in .pdf format

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Read also